Exploring the Diagnostic Performance of Dynamic Chest Radiology in Chronic Obstructive Pulmonary Disease
NCT ID: NCT06653413
Last Updated: 2024-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
600 participants
OBSERVATIONAL
2024-01-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach(Radiogenomics-Lung)
NCT06500312
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
NCT03357094
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
NCT06742021
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
NCT04984148
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
NCT07059923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The severity of COPD is diagnosed and assessed mainly by pulmonary function examination. Lung capacity, lung volume, and lung diffusion capacity can be determined by a lung function test to assess the health of lung function. Airflow limitation is an important diagnostic criterion, and the key indicator for determining airflow limitation is the one-second rate (FEV1/FVC) less than 0.7 after inhalation of bronchodilators. The percentage of measured forced expiratory volume in the first second to the estimated value (FEV1%pred) was the primary parameter for assessing the severity of COPD. However, some literature has pointed out that FEV1%pred does not fully reflect the clinical symptoms and quality of life of patients. Although pulmonary function examination is of great significance in evaluating patients' lung conditions, it can not fully evaluate small airway lesions and lung parenchymal injury, and there are problems of non-standard and inaccurate data. Due to the low rate of pulmonary function examination, it can not fully represent the lung condition of patients, and it is still necessary to combine other examination methods to comprehensively evaluate the lung health status of patients.
Dynamic Chest Radiography (DCR) is a real-time X-ray imaging system that takes continuous images of a moving chest, usually in 10 to 20 seconds, and is a fast, well-tolerated, and simple chest radiography technique. Measurements of diaphragm movement, lung area, and lung perfusion can provide multiple examination information for COPD patients and supplement baseline deficiencies in critically ill patients.
The purpose of this study was to evaluate the dynamic chest radiography of COPD patients based on Chinese population, analyze the characteristics of dynamic chest radiography of COPD patients, and study the correlation between chest radiography and lung function. To study the value of dynamic chest radiography in diagnosing COPD. To investigate the role of dynamic chest radiography in evaluating the severity of airflow restriction in COPD and predicting the clinical outcome of COPD. Through multidimensional dynamic assessment of patients, dynamic chest radiography can help doctors more accurately diagnose patients' conditions, and timely interventional treatment, so as to reduce the occurrence of acute exacerbations, delay the risk of disease progression, and improve patients' quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD group
any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC \<0.7 after bronchodilator was used to confirm COPD.
No interventions assigned to this group
normal group
No acute or chronic cardiopulmonary disease in the past, no abnormal lung physical examination and lung imaging examination in the past month, no history of infectious diseases.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Normal Group: (1) Age ≥30 years old and ≤ 80 years old; (2) Normal pulmonary ventilation function; (3) Exclude chronic airway diseases (such as COPD, asthma, bronchiectasis, etc.); (4) Signing informed consent; (5) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds).
Exclusion Criteria
40 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laiyu Liu, professor
Role: STUDY_CHAIR
Nanfang Hospital, Southern Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Locations
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
32470763
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NFEC-2024-158
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.